HEALTH AND SAFETY

» Drug, Devices, and Supplements

» Physician Accountability

» Consumer Product Safety

» Worker Safety

» Health Care Delivery

» Auto and Truck Safety

» Global Access to Medicines

» Infant Formula Marketing

 

More Information on Alosetron (Lotronex)

Press Release: Don't Allow Alosetron (Lotronex) Back on the Market

June 7, 2002

Reintroducing Lotronex onto the market as announced today by the U.S. Food and Drug Administration (FDA) will endanger patients, Public Citizen said today. Not only is the new marketing program too lax to prevent harm, but it is to be overseen by the company that makes the drug — a poor idea because the company has a financial incentive to downplay problems with the drug. Also, the recommended dose has not been shown to be effective.

Lotronex, approved in February 2000 to treat irritable bowel syndrome (IBS) for women with diarrhea as the predominant symptom, was withdrawn from the market in November 2000 because of dangerous adverse effects experienced by some patients taking it. Public Citizen in August 2000 petitioned the FDA to remove the drug because of evidence that it caused ischemic colitis, a life-threatening condition in which bowel tissue dies as a result of a lack of blood flow to the colon. Many patients were hospitalized and suffered permanent injuries.

Today, the FDA announced plans to reintroduce Lotronex at a recommended dose of 1 milligram per day. However, studies conducted prior to the original approval showed no evidence that the 1 mg daily dose is significantly better than a placebo. Further, the trials showed an increased risk of adverse effects at the 1 mg dose — a four-fold increase in constipation severe enough to cause the patients to withdraw from the study – compared with placebo. Thus, the newly approved starting dose of 1 mg per day lacks the proper evidence of efficacy required by the 1962 FDA Drug Efficacy Amendments but causes a significantly greater incidence of severe constipation. In addition, in 12 percent of the first 70 cases of ischemic colitis reported to the FDA, the patient was using the 1 mg per day dose approved for the new marketing plan.

Under the guidelines announced today, physicians who want to prescribe the drug must state that they are qualified to diagnose IBS and manage ischemic colitis and that they understand the risks associated with Lotronex. The doctors also must promise to educate patients about the risks and obtain their signatures on a patient-physician agreement.

However, no one is required to verify the doctors’ qualifications or check to ensure patients have been informed of the drug’s risks. Further, there will be no mandatory tracking of patients to see if they develop adverse effects. Finally, the entity administering the program will be GlaxoSmithKline, the drug’s manufacturer.

"This is a classic case of the fox guarding the hen house," said Larry Sasich, a pharmacist and research analyst with Public Citizen’s Health Research Group. "GlaxoSmithKline has a huge stake in this drug and wants it to succeed. The company should not be overseeing the patient safety program."

Instead, the FDA should have limited the drug to research status, which requires tight controls on who receives a drug and documentation of the effectiveness and safety of a drug. Under that status, the FDA should have limited the drug to women who had previously used it and experienced no adverse effects, Sasich said.

Also, at a minimum, the risk management program should be restricted to registered gastroenterologists, Sasich said. There should be a patient registry, and the pharmacies that dispense the drug also should be registered with the FDA.

"We are quite fearful for patients," Sasich said. "Unfortunately, the FDA’s action will almost surely lead to more injuries and possibly deaths associated with this drug."

Read Public Citizen’s petition to have Lotronex removed from the market.

Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.